Schrödinger, Inc.
NASDAQ:SDGRMedical - Healthcare Information Services
+$0.00 today
- Market cap
- $1.79B
- Beta
- 1.64
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$1.40
Volume 1.18M
Average 1.35M
SDGR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Schrödinger, Inc.NASDAQ: SDGR
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income grows, but more slowly than its trailing trend
Q3 FY2026 net income of $37.71M (cash outflow) rose 15.0% year over year, behind the +125.0% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -11.5% a year.
Context
- Net income amounted to 40.4% of revenue in FY2025, down 49.8 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$107.8M (+4.4%) for the fiscal year ending Dec 2026, a step up from the -44.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$37.71M-731.1% QoQ
- Last fiscal yearDec 2025
- -$103.27M-44.8% YoY
- LTMSep 2026
- $44.01M+125.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.0% | -114.1% | -129.1 pp |
| 1 year | -44.8% | +4.4% | +49.2 pp |
| 3-year CAGR | -11.5% | -26.3% | -14.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (103.27M) USD
- Year-over-year change
- +44.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (103.27M) | +44.8% |
| FY2024 | 2024-12-31 | (187.12M) | -559.5% |
| FY2023 | 2023-12-31 | 40.72M | +127.3% |
| FY2022 | 2022-12-31 | (149.19M) | -47.4% |
| FY2021 | 2021-12-31 | (101.22M) | — |
Net Income vs competitors
How SDGR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +125.0% is the 2nd highest of 9, against a peer median of +1.7%.
- Net income amounts to 16.3% of revenue for SDGR, versus a peer median of 78.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.01B USD | +25.3% | +23.1% | 29.3% | |
| LTM Jun 2026 | $286.04M USD | -8.2% | -1.6% | 2763.6% | |
GENBGenerate Biomedicines, Inc. | FY2025 | $222.97M USD | +22.9% | — | 699.1% |
| LTM Sep 2026 | $191.46M USD | +11.5% | — | 282.2% | |
| LTM Feb 2026 | $62.79M USD | -964.8% | — | 78.0% | |
| LTM Sep 2026 | $44.01M USD | +125.0% | -11.5% | 16.3% | |
| LTM Mar 2026 | $15.91M USD | -19.9% | +6.3% | — | |
| LTM Mar 2026 | $15.1M USD | +475.3% | — | 3.6% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$12.18M CAD | -73.6% | +21.9% | 66.4% |
| Peer median (excluding SDGR) | — | +1.7% | +14.1% | 78.0% | |
Competitors are the stored peer set for SDGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (101.22M) | (149.19M) | 40.72M | (187.12M) | (103.27M) |
| Depreciation & Amortization | 2.85M | 4.34M | 5.55M | 6.16M | 6.02M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.49M | 39.63M | 47.84M | 49.9M | 43M |
| Change in Working Capital | 4.68M | (21.38M) | (22.55M) | (13.04M) | 118.17M |
| Accounts Receivables | (5.51M) | (27.95M) | (20.03M) | (166.22M) | 150.94M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (411K) | 1.18M | 7.32M | (6.12M) | 908K |
| Other Working Capital | 10.6M | 5.39M | (9.85M) | 159.3M | (33.68M) |
| Other Non-Cash Items | (3.46M) | 6.91M | (208.29M) | (13.27M) | (50.02M) |
| Operating Cash Flow | (70.67M) | (119.68M) | (136.73M) | (157.37M) | 13.9M |
| Capital Expenditures | (7.17M) | (8.01M) | (13.4M) | (7.31M) | (1.44M) |
| Acquisitions (Net) | 0 | (7.03M) | (4.13M) | 45.73M | 0 |
| Purchases of Investments | (418.5M) | (271.47M) | (320.62M) | (251.34M) | (312.96M) |
| Sales of Investments | 408.48M | 364.71M | 383.97M | 361.76M | 372.3M |
| Other Investing Activities | 375K | 11.83M | 147.21M | 0 | 0 |
| Investing Cash Flow | (16.81M) | 90.02M | 193.03M | 148.84M | 57.9M |
| Debt Repayment | 0 | 0 | (19K) | (58K) | (58K) |
| Common Stock Issued | 0 | 0 | 0 | 8.87M | 2.99M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.95M | 2.11M | 9.07M | 1.31M | 0 |
| Financing Cash Flow | 7.95M | 2.11M | 9.05M | 10.12M | 2.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (79.53M) | (27.55M) | 65.35M | 1.59M | 74.73M |
| Free Cash Flow | (77.84M) | (127.7M) | (150.14M) | (164.68M) | 12.46M |
Schrödinger, Inc.
NASDAQ:SDGR
Intrinsic Alpha fair value
Locked
Current Price
$27.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.